Literature DB >> 10564746

Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys.

E Decamp1, T Wade, J S Schneider.   

Abstract

The contribution of the duration of the striatal dopamine (DA) depletion and the expression of parkinsonian signs to changes in D(1) and D(2) receptor number was investigated in the present study. Some animals (N=4) received large doses of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) over short periods of time and were symptomatic for a short period of time (1-3 months; acute parkinsonian group). Other animals (N8 months; chronic parkinsonian group). Despite similar symptomatology and similar degrees of striatal DA denervation, only acute parkinsonian animals had significantly increased numbers of D(1) receptors in most striatal regions. Striatal D(2) receptor binding was elevated in acute parkinsonian monkeys but only in some lateral striatal subregions at mid and caudal levels. These findings further suggest that the duration of parkinsonism is a critical factor in modulating changes in striatal neurochemistry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564746     DOI: 10.1016/s0006-8993(99)02015-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Inhibitory effects of lysophosphatidylcholine on the dopaminergic system.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Kennie R Shepherd; Nazarius S Lamango; Karam F A Soliman; Clivel G Charlton
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

Review 3.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

4.  Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy.

Authors:  Ludovic Leriche; Tomas Björklund; Nathalie Breysse; Laurent Besret; Marie-Claude Grégoire; Thomas Carlsson; Frédéric Dollé; Ronald J Mandel; Nicole Déglon; Philippe Hantraye; Deniz Kirik
Journal:  J Neurosci       Date:  2009-02-04       Impact factor: 6.167

Review 5.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease.

Authors:  Luca Passamonti; Maria Salsone; Nicola Toschi; Antonio Cerasa; Marco Giannelli; Carmelina Chiriaco; Giuseppe Lucio Cascini; Francesco Fera; Aldo Quattrone
Journal:  Brain Behav       Date:  2013-03-22       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.